Nepafenac

證據等級: L5

預測適應症: 10 個

Nepafenac: From Cataract Surgery Inflammation to Eye Disease

One-Sentence Summary

Nepafenac is a topical ophthalmic prodrug NSAID internationally approved for the prevention and treatment of pain and inflammation associated with cataract surgery, but currently not registered in India. The TxGNN model predicts it may be effective for Eye Disease broadly, with 41 clinical trials identified in support — this represents both a strong repurposing signal and a regulatory market entry opportunity.

Quick Overview

Item	Content
Original Indication	Pain and inflammation associated with cataract surgery (internationally approved; no India CDSCO registration)
Predicted New Indication	Eye Disease
TxGNN Prediction Score	99.85%
Evidence Level	L1
India Market Status	Not Marketed
Number of Registrations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Detailed mechanism of action data from DrugBank was not retrieved in this Evidence Pack. Based on the available repurposing rationale, Nepafenac is a COX-1/COX-2 dual inhibitor prodrug. When applied topically to the eye, it penetrates the cornea and is hydrolyzed by intraocular hydrolases into its active metabolite amfenac. Amfenac then inhibits the cyclooxygenase pathway, suppressing the synthesis of prostaglandins (PGE2, PGF2α) that drive postoperative ocular inflammation and pain. Importantly, it also inhibits VEGF-induced retinal vascular permeability, providing a secondary mechanism that helps prevent diabetic macular edema following cataract surgery — an indication directly supported by multiple Phase 3 RCTs.

The TxGNN model’s top prediction of “Eye Disease” is mechanistically entirely consistent with Nepafenac’s established clinical profile. The drug (marketed as Nevanac® 0.1% and Ilevro® 0.3%) has received regulatory approval from the US FDA and in multiple international markets. The model’s high confidence score (99.85%) reflects recognition of the strong drug–disease alignment across the ocular inflammation, macular edema, and post-surgical pain landscape. Beyond classical repurposing, this prediction highlights a genuine unmet market need in India: a well-validated, globally approved ophthalmic NSAID with no current CDSCO registration.

Clinical evidence is particularly notable for Asian populations — a completed Phase 3 RCT (NCT01426854) was conducted specifically in Chinese cataract surgery patients, providing geographically proximate efficacy data that strengthens the case for South Asian regulatory submission.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01109173	Phase 3	Completed	2,120	Safety and efficacy of Nepafenac 0.3% for prevention and treatment of ocular inflammation and pain after cataract surgery — largest Phase 3 trial in the programme
NCT01318499	Phase 2	Completed	1,342	Dose-finding: Nepafenac 0.3% vs 0.1% vs vehicle for post-cataract inflammation — primary basis for the 0.3% once-daily formulation approval
NCT01853072	Phase 3	Completed	881	Nepafenac 0.3% vs vehicle in diabetic patients post-cataract surgery — demonstrated superiority in macular edema outcomes
NCT01872611	Phase 3	Completed	819	Replicate Phase 3 trial of Nepafenac 0.3% in diabetic cataract patients — confirmed superiority over vehicle
NCT03499873	Phase 3	Completed	448	Bioequivalence RCT: generic Nepafenac 0.3% vs branded Ilevro® — supports generic regulatory pathway
NCT01426854	Phase 3	Completed	260	Nepafenac 0.1% vs placebo in Chinese subjects post-cataract surgery — directly relevant to Asian/South Asian populations
NCT00405730	Phase 3	Completed	227	Nepafenac 0.1% vs Ketorolac vs placebo for cataract surgery inflammation — pivotal European registration study
NCT00782717	Phase 2	Completed	263	Nevanac 0.1% vs vehicle in diabetic retinopathy patients — efficacy and safety evidence supporting the macular edema extension
NCT01331005	Phase 2	Completed	125	Topical NSAIDs (including Nepafenac) for non-central diabetic macular edema — assessed retinal volume changes vs placebo by OCT
NCT00818844	Phase 4	Completed	40	Nepafenac 0.1% vs placebo for reducing macular volume after epiretinal membrane surgery — direct post-market efficacy evidence

Literature Evidence

Currently no related literature available for this specific indication query.

India Market Information

Nepafenac currently has no registered products with the CDSCO in India. No authorization records are available.

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple large Phase 3 RCTs across global and Asian populations confirm the safety and efficacy of Nepafenac 0.1% and 0.3% ophthalmic suspensions for cataract surgery-associated inflammation and macular edema; the L1 evidence base is sufficient for a CDSCO new drug application. The primary risk is not clinical uncertainty but regulatory and manufacturing pathway gaps specific to India.

To proceed, the following is needed:

Obtain and review the full package insert (USPI/SmPC) to extract warnings, contraindications, and drug interactions for India-specific safety assessment
Confirm local manufacturing or import partner (Indoco Remedies, which already participated in NCT03499873 bioequivalence study, is a potential Indian manufacturing partner)
Assess whether the CDSCO will accept existing global Phase 3 data or require a bridging study in Indian patients
Obtain DrugBank API data on Nepafenac’s complete MOA, pharmacokinetics, and known interaction profile to complete the regulatory dossier
Define the target product label: decide between 0.1% TID (Nevanac®) and 0.3% QD (Ilevro®) formulation strategies for the Indian market
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.